According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “
A number of other equities research analysts have also recently commented on YMAB. Cowen reiterated a buy rating on shares of Y-mAbs Therapeutics in a report on Monday, July 1st. Wedbush started coverage on Y-mAbs Therapeutics in a report on Tuesday, September 3rd. They set an outperform rating and a $38.00 target price on the stock. Finally, HC Wainwright set a $40.00 target price on Y-mAbs Therapeutics and gave the company a buy rating in a report on Monday, August 26th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $32.50.
Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). Research analysts expect that Y-mAbs Therapeutics will post -2.1 EPS for the current fiscal year.
In other Y-mAbs Therapeutics news, insider Thomas Gad sold 4,000 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $22.54, for a total transaction of $90,160.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Johan Wedell-Wedellsborg sold 168,244 shares of the stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $27.57, for a total value of $4,638,487.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 344,010 shares of company stock worth $9,324,188. 38.40% of the stock is owned by insiders.
Several institutional investors have recently modified their holdings of YMAB. BlackRock Inc. lifted its stake in shares of Y-mAbs Therapeutics by 212.6% during the 2nd quarter. BlackRock Inc. now owns 1,153,831 shares of the company’s stock worth $26,387,000 after purchasing an additional 784,672 shares during the period. Artal Group S.A. purchased a new position in shares of Y-mAbs Therapeutics during the 2nd quarter worth $9,148,000. Cormorant Asset Management LP lifted its stake in shares of Y-mAbs Therapeutics by 39.8% during the 2nd quarter. Cormorant Asset Management LP now owns 1,000,000 shares of the company’s stock worth $22,870,000 after purchasing an additional 284,518 shares during the period. Vanguard Group Inc. lifted its stake in shares of Y-mAbs Therapeutics by 72.0% during the 2nd quarter. Vanguard Group Inc. now owns 489,582 shares of the company’s stock worth $11,196,000 after purchasing an additional 205,021 shares during the period. Finally, AXA purchased a new position in shares of Y-mAbs Therapeutics during the 2nd quarter worth $3,560,000. 32.06% of the stock is currently owned by institutional investors.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Featured Story: Do Tariffs Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.